Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8273a and Nivolumab in Unresectable Melanoma
NCT02983006Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- Oct 2016
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of DS-8273a in melanoma, sponsored by NYU Langone Health. Primary endpoint: Adverse Events at 2 years. Started Oct 2016; status: completed.
02
Drugs
DS-8273a
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02983006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983006.